Morlipar 200 Mg 200 mg Capsule
PDF Leaflet Revision Date: 04 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate COVID-19 in adults at risk for severe illness.
Dosage (summary)
800 mg (four 200 mg capsules) every 12 hours for 5 days.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding during treatment and for 4 days after.
Contraindications
- Hypersensitivity to molnupiravir or excipients
Common side effects
- Diarrhoea
- Nausea
- Dizziness
- Headache
Counselling Points
- Take with or without food
- Do not double dose for missed doses
- Use effective contraception during treatment
Important Disclaimer
The Morlipar 200 Mg 200 mg Capsule professional information leaflet below is the property of Strides Pharm (Sa) and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
